PRAX News and Press, Praxis Precision Medicines Inc. From 03/26/24

2024-03-26 08:54:38 ET Praxis Precision Medicines ( NASDAQ: PRAX ) added ~20% premarket Tuesday after the company said its experimental oral therapy PRAX-628 led to a 100% complete response in a mid-stage trial for patients with photo paroxysmal response, a characteristic of epi...

In the 45 mg cohort, 100% of patients achieved a complete response In the 15 mg cohort, 80% of patients achieved a complete response and 20% achieved a partial response Safety was consistent with prior dose escalation study and PK analysis confirmed therapeutic exposures P...

Presentation will be held virtually on Tuesday, March 26, 2024 at 8:00 a.m. ET Praxis leadership will be joined by key opinion leader in epilepsy Dr. Daniel Friedman, Professor of Neurology at NYU Grossman School of Medicine BOSTON, March 25, 2024 (GLOBE NEWSWIRE) -- Praxis Pr...

2024-03-06 13:06:02 ET More on Praxis Precision Medicines Praxis Precision Medicines falls after pricing of $150M equity offering Read the full article on Seeking Alpha For further details see: Praxis Precision Medicines GAAP EPS of -$2.97 misses by $0.92, revenu...

2024-03-05 11:12:10 ET More on Praxis Precision Medicines Biggest stock movers today: Hertz Global, Crypto-linked stocks, Southwestern Energy, and more Praxis Precision Medicines falls after pricing of $150M equity offering Seeking Alpha’s Quant Rating on Prax...

Over 3,000 referrals received to date meet pre-qualifying eligibility criteria for ulixacaltamide Phase 3 studies in the Essential3 program for essential tremor (ET); enrollment on track to be completed in 1H 2024 with topline results in 2H 2024 Topline results from the PRAX-628...

Carisma Therapeutics Inc. (CARM) is expected to report $-0.56 for Q4 2023 First Acceptance Corp. (FACO) is expected to report for quarter end 2023-12-31 Bell Copper Corp (BCUFF) is expected to report for quarter end 2023-12-31 BioHarvest Sciences Inc (CNVCF) is expected to report for ...

BOSTON, March 01, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imb...

First Solar Inc. (FSLR) is expected to report $3.19 for Q4 2023 VIZIO Holding Corp. Class A (VZIO) is expected to report $0.02 for Q4 2023 Henry Schein Inc. (HSIC) is expected to report $0.71 for Q4 2023 Republic Services Inc. (RSG) is expected to report $1.28 for Q4 2023 Forge Gl...

2024-02-26 06:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...